Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

In patients with heart failure, few data describe the neurohormonal response to nesiritide and furosemide either alone or in combination.

This study systematically compared the effects of nesiritide, furosemide, and their combination on natriuresis/diuresis and plasma aldosterone in patients with chronic stable heart failure who were relatively diuretic resistant.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Twenty-eight subjects completed a multicenter, open-label, three-arm crossover study.

How the Study Was Run

The researchers set it up as a randomized, open-label, crossover and multicenter study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Everyone knew when BNP (Nesiritide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the participants took both BNP (Nesiritide) and the comparison in turn, acting as their own control.

Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Aldosterone, Biomarkers, Drug Resistance, Furosemide, Heart Failure, Natriuresis and Natriuretic Agents.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of BNP (Nesiritide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Clinical cardiology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.